Immuneering Corp IMRX
- atebimetinib — Pancreatic Ductal Adenocarcinoma Phase 3
- atebimetinib — Non-Small Cell Lung Cancer
- atebimetinib — Melanoma Phase 1
- envometinib Phase 1
- atebimetinib — Advanced Solid Tumors Phase 1
MEK (1 companies · 5 programs)
Companies with an active program directed at MEK.